2023 World Conference on Lung Cancer (Posters)-EP07.02. MIDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients

EP07.02. MIDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients - PDF(Slides)

Back to course

Pdf Summary

In a phase 1a clinical trial, researchers explored the safety and efficacy of an autologous dendritic cell (DC) vaccine targeting neoantigens in non-small cell lung cancer (NSCLC) patients. The study aimed to induce robust and durable expansion of tumor antigen-specific T-cells, as this is a high unmet need in lung cancer treatment. Neoantigens were selected based on the patient's individual tumor genome, transcriptome, and immunopeptidome. The DCs were generated using a proprietary method and presented mRNA-encoded neoepitopes. <br /><br />Out of the 10 enrolled patients, 6 had successful production and administration of the Neo-mDCs. The treatment showed an excellent safety profile, with no grade 3-4 treatment-related toxicity observed. Three patients were free of relapse at the time of analysis. The vaccine-induced T-cell responses were detected in 5 out of 6 treated patients, and neoantigen-specific T-cells were elicited even at the lowest dose level. Moreover, the responses persisted up to 1.5 years after the last dose. The vaccine-induced T-cells exhibited a wide range of functional states, with no features of exhaustion.<br /><br />The study demonstrates the manufacturing feasibility and safety of the autologous DC vaccine targeting neoantigens. It shows the potential to evoke robust and durable tumor neoantigen-specific T-cell responses in NSCLC patients. The therapy has the potential to convert "cold" tumors into T-cell rich "hot" tumors, suggesting a possible combination with immune checkpoint inhibitors. The findings support further investigation into the efficacy of the vaccine in larger clinical trials. Overall, this study highlights the potential of personalized immunotherapy approaches in improving outcomes for NSCLC patients.

Asset Subtitle

Karim Vermaelen

Meta Tag

Speaker Karim Vermaelen

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

phase 1a clinical trial

autologous dendritic cell vaccine

neoantigens

non-small cell lung cancer

tumor antigen-specific T-cells

safety profile

vaccine-induced T-cell responses

functional states of T-cells

manufacturing feasibility

personalized immunotherapy approaches